Kontakt
Address and Contact
Neurologische Universitätsklinik Heidelberg
Im Neuenheimer Feld 400
69120 Heidelberg
+49 (0)6221 56 34391
lisa.langbein@med.uni-heidelberg.de
UNITE Spokesperson
Wick, Wolfgang, Prof. Dr. med.
UNITE Spokesperson & Chairman
University Hospital Heidelberg, Department of Neurology / Neurooncology & DKFZ, Clinical Cooperation Unit Neurooncology, Im Neuenheimer Feld 400, 69120 Heidelberg, Germany
UNITE Coordination Office
Langbein, Lisa, M.P.A.
Project Coordinator
University Hospital Heidelberg, Department of Neurology, Im Neuenheimer Feld 400, 69120 Heidelberg, Germany
+49 (0)6221 56 34391
lisa.langbein@med.uni-heidelberg.de
Address
Im Neuenheimer Feld 400
69120 Heidelberg
Themen
Research
- Focus A
- A01: Targeting tumor cell networks to overcome primary and adaptive resistance in glioblastoma
- A02: Development of a specific combination therapy for histone H3-mutant pediatric glioblastoma
- A03: Deciphering resistance against targeted treatments
- A04: Evolution of IDH mutant gliomas during malignant progression
- A05: Predictive biomarkers for MGMT-promoter-methylated glioblastoma
- A06: Resistance mechanisms of glioblastoma against alkylating agents and radiotherapy
Research
- Focus B
- B01: Mechanisms of response and resistance to checkpoint blockade in gliomas
- B02: DNA mis-match repair regulates immune checkpoint blockade therapy in glioblastoma
- B03: Targeting immunosuppressive programs in isocitrate dehydrogenase mutant gliomas
- B04: Impact of myeloid cells on the adaptive immune response in IDH1-mutant glioblastomas
- B05: Dissecting the response of glioblastoma and its tumor microenvironment to focused high-dose radiotherapy
Research
- Focus C
- C01: Comprehensive preclinical pharmacology testing of drugs used for glioblastoma treatment in children and adults
- C02: Radiomics, radiogenomics and deep-learning in neurooncology
- C03: Imaging immune signatures of glioma response and resistance towards immunotherapy
- C04: Identification and spatial mapping of metabolic resistance factors by MALDI mass spectrometry imaging
- C05: Overcoming glioma radio-resistance with particle therapy